• Barclays sets a price target of $71 for NASDAQ:DXCM, indicating a potential upside of approximately 1.91%.
• Dexcom announces preliminary, unaudited financial results for Q4 and fiscal year 2025, with an initial outlook for 2026.
• The company's stock has experienced significant price fluctuations over the past year, with a high of $93.25 and a low of $54.11.

Dexcom, Inc. (NASDAQ:DXCM) is a prominent player in the medical technology sector, specializing in continuous glucose monitoring systems for diabetes management. The company is headquartered in San Diego and competes with other medical device companies like Abbott Laboratories and Medtronic. On January 12, 2026, Barclays set a price target of $71 for DXCM, while the stock was trading at $69.67, indicating a potential upside of approximately 1.91%.

Dexcom recently announced its preliminary, unaudited financial results for the fourth quarter and fiscal year 2025, as highlighted by Business Wire. The company also provided an initial outlook for 2026. This announcement comes at a time when the stock price is $68.96, reflecting a 2.31% increase or $1.56. The stock has traded between $65.92 and $70.61 today.

Over the past year, DXCM has experienced significant price fluctuations, reaching a high of $93.25 and a low of $54.11. Despite these fluctuations, the company maintains a market capitalization of approximately $26.98 billion. This indicates investor confidence in Dexcom's growth potential and market position.

Today's trading volume for DXCM is 1,976,722 shares, suggesting active investor interest. The stock's performance and Barclays' price target reflect the market's anticipation of Dexcom's future growth, supported by its recent financial announcements and strategic outlook for 2026.